151 related articles for article (PubMed ID: 22971094)
21. Poly(ADP-ribose) polymerase-1 inhibition increases expression of heat shock proteins and attenuates heat stroke-induced liver injury.
Mota RA; Hernández-Espinosa D; Galbis-Martinez L; Ordoñez A; Miñano A; Parrilla P; Vicente V; Corral J; Yélamos J
Crit Care Med; 2008 Feb; 36(2):526-34. PubMed ID: 18091544
[TBL] [Abstract][Full Text] [Related]
22. PARP-1 inhibition induces a late increase in the level of reactive oxygen species in cells after ionizing radiation.
Cieślar-Pobuda A; Saenko Y; Rzeszowska-Wolny J
Mutat Res; 2012 Apr; 732(1-2):9-15. PubMed ID: 22321899
[TBL] [Abstract][Full Text] [Related]
23. Poly(ADP-ribose) polymerase inhibition as a novel therapeutic approach against intraepidermal nerve fiber loss and neuropathic pain associated with advanced diabetic neuropathy: a commentary on "PARP Inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy".
Pacher P
Free Radic Biol Med; 2008 Mar; 44(6):969-71. PubMed ID: 18194675
[No Abstract] [Full Text] [Related]
24. Protective effects of 4-amino1,8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy.
Sharma SS; Kumar A; Kaundal RK
Life Sci; 2008 Mar; 82(11-12):570-6. PubMed ID: 18262571
[TBL] [Abstract][Full Text] [Related]
25. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations.
Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ
Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158
[TBL] [Abstract][Full Text] [Related]
26. Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy.
Negi G; Kumar A; Sharma SS
Biochem Biophys Res Commun; 2010 Jan; 391(1):102-6. PubMed ID: 19900402
[TBL] [Abstract][Full Text] [Related]
27. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.
Bartha E; Solti I; Kereskai L; Lantos J; Plozer E; Magyar K; Szabados E; Kálai T; Hideg K; Halmosi R; Sumegi B; Toth K
Cardiovasc Res; 2009 Aug; 83(3):501-10. PubMed ID: 19443425
[TBL] [Abstract][Full Text] [Related]
28. Potential role of poly(ADP-ribose) polymerase (PARP) activation in methotrexate-induced nephrotoxicity and tubular apoptosis.
Dalaklioglu S; Sahin P; Ordueri EG; Celik-Ozenci C; Tasatargil A
Int J Toxicol; 2012; 31(5):430-40. PubMed ID: 22914891
[TBL] [Abstract][Full Text] [Related]
29. A review on PARP1 inhibitors: Pharmacophore modeling, virtual and biological screening studies to identify novel PARP1 inhibitors.
Singh SS; Sarma JA; Narasu L; Dayam R; Xu S; Neamati N
Curr Top Med Chem; 2014; 14(17):2020-30. PubMed ID: 25262797
[TBL] [Abstract][Full Text] [Related]
30. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity.
Kim J; Long KE; Tang K; Padanilam BJ
Kidney Int; 2012 Jul; 82(2):193-203. PubMed ID: 22437413
[TBL] [Abstract][Full Text] [Related]
31. Mild activation of poly(ADP-ribose) polymerase (PARP) is neuroprotective in rat hippocampal slice models of ischemic tolerance.
Gerace E; Scartabelli T; Formentini L; Landucci E; Moroni F; Chiarugi A; Pellegrini-Giampietro DE
Eur J Neurosci; 2012 Jul; 36(1):1993-2005. PubMed ID: 22639866
[TBL] [Abstract][Full Text] [Related]
32. PARP1 is required for adhesion molecule expression in atherogenesis.
von Lukowicz T; Hassa PO; Lohmann C; Borén J; Braunersreuther V; Mach F; Odermatt B; Gersbach M; Camici GG; Stähli BE; Tanner FC; Hottiger MO; Lüscher TF; Matter CM
Cardiovasc Res; 2008 Apr; 78(1):158-66. PubMed ID: 18093987
[TBL] [Abstract][Full Text] [Related]
33. Poly(ADP-ribosyl)ation enhancement in brain cell nuclei is associated with diabetic neuropathy.
Kuchmerovska T; Shymanskyy I; Donchenko G; Kuchmerovskyy M; Pakirbaieva L; Klimenko A
J Diabetes Complications; 2004; 18(4):198-204. PubMed ID: 15207836
[TBL] [Abstract][Full Text] [Related]
34. Poly(ADP-Ribose) Polymerase Inhibition Improves Corneal Epithelial Innervation and Wound Healing in Diabetic Rats.
Byun YS; Kang B; Yoo YS; Joo CK
Invest Ophthalmol Vis Sci; 2015 Feb; 56(3):1948-55. PubMed ID: 25711635
[TBL] [Abstract][Full Text] [Related]
35. Treatment with Actovegin® improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation.
Dieckmann A; Kriebel M; Andriambeloson E; Ziegler D; Elmlinger M
Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):132-8. PubMed ID: 22020669
[TBL] [Abstract][Full Text] [Related]
36. Poly(ADP-ribose) polymerase-1 protects excessive DNA strand breaks from deterioration during repair in human cell extracts.
Parsons JL; Dianova II; Allinson SL; Dianov GL
FEBS J; 2005 Apr; 272(8):2012-21. PubMed ID: 15819892
[TBL] [Abstract][Full Text] [Related]
37. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations.
Alano CC; Kauppinen TM; Valls AV; Swanson RA
Proc Natl Acad Sci U S A; 2006 Jun; 103(25):9685-90. PubMed ID: 16769901
[TBL] [Abstract][Full Text] [Related]
38. Role for DNA damage signaling in pulmonary arterial hypertension.
Meloche J; Pflieger A; Vaillancourt M; Paulin R; Potus F; Zervopoulos S; Graydon C; Courboulin A; Breuils-Bonnet S; Tremblay E; Couture C; Michelakis ED; Provencher S; Bonnet S
Circulation; 2014 Feb; 129(7):786-97. PubMed ID: 24270264
[TBL] [Abstract][Full Text] [Related]
39. Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice.
Drel VR; Pacher P; Stavniichuk R; Xu W; Zhang J; Kuchmerovska TM; Slusher B; Obrosova IG
Int J Mol Med; 2011 Oct; 28(4):629-35. PubMed ID: 21617845
[TBL] [Abstract][Full Text] [Related]
40. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.
Wang B; Qian H; Yiu SM; Sun J; Zhu G
Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
